5 Best Vaccine Stocks To Buy Now

1. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 83

Johnson & Johnson (NYSE:JNJ) is an industry leader and has a proven track record of successfully executing its growth strategies. The company is also a dividend aristocrat, and its dividend yield sits at 2.62%, as of October 28. The company has a defensive business model and investors can rely on it for both growth and income. Johnson & Johnson (NYSE:JNJ)  is ranked high among the best vaccine stocks to buy now.

On October 18, Johnson & Johnson (NYSE:JNJ) announced market-beating earnings for the fiscal third quarter of 2022. The company reported earnings per share of $2.55 and outperformed EPS estimates by $0.06. The company generated a revenue of $23.79 billion and beat expectations by $357.9 million.

On October 19, Bernstein analyst Lee Hambright revised his price target on Johnson & Johnson (NYSE:JNJ) to $190 from $194 and maintained a Market Perform rating on the shares. This October, Barclays analyst Matt Miksic took coverage of Johnson & Johnson (NYSE:JNJ) with an Equal Weight rating and a $175 price target.

At the close of Q2 2022, 83 hedge funds were long Johnson & Johnson (NYSE:JNJ) and held stakes worth $6.76 billion in the company. Of those, GQG Partners was the most prominent shareholder and disclosed stakes of $1.16 billion in the company.

Here is what Distillate Capital Partners LLC had to say about Johnson & Johnson (NYSE:JNJ) in its second-quarter 2022 investor letter:

“Johnson & Johnson was among the 2 largest trims at around 1% each. Each stock was up 1% in the quarter compared to the 16% price decline for the S&P 500 and the positions were reduced as the valuations became somewhat less appealing, though still attractive enough to warrant inclusion.”

You can also take a look at Best Value Stocks To Buy According To Warren Buffett and Best Stocks For Beginners with Little Money.

Follow Insider Monkey on Twitter